<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212469</url>
  </required_header>
  <id_info>
    <org_study_id>2016-003293-40</org_study_id>
    <secondary_id>2016/2454</secondary_id>
    <nct_id>NCT03212469</nct_id>
  </id_info>
  <brief_title>A Trial of Durvalumab and Tremelimumab in Comibination With SBRT in Patients With Metastatic Cancer</brief_title>
  <acronym>ABBIMUNE</acronym>
  <official_title>A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, or Oesophageus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an open label, paucicentric, Phase I/II trial aiming to evaluate the safety, the
      clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating
      Durvalumab in conjunction with SBRT or Durvalumab + Tremelimumab in conjunction with SBRT in
      patients with metastatic squamous cell carcinoma of head and neck, lung, or esophagus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is an open label, paucicentric, Phase I/II trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Approximatly 8 weeks</time_frame>
    <description>Event possibly related to study drugs and fulfills any one of the following criteria using CTCAE Version 4.03</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Lung Cancer</condition>
  <condition>Oesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with head and neck squamous cell carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients lung cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with oesophagus cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses
Safety run of the triple combination:
Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,
Efficacy step
Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with
SBRT at C1D15, then
Durvalumab Q4W alone for up to 9 additional doses</description>
    <arm_group_label>Patients with head and neck squamous cell carcinoma</arm_group_label>
    <arm_group_label>Patients lung cancer</arm_group_label>
    <arm_group_label>Patients with oesophagus cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>Preliminary steps : Safety Runs
Safety run of the triple combination:
Tremelimumab at 75mg/Q4W for up to 4 doses
Efficacy step
Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with
SBRT at C1D15, then
Durvalumab Q4W alone for up to 9 additional doses</description>
    <arm_group_label>Patients with head and neck squamous cell carcinoma</arm_group_label>
    <arm_group_label>Patients lung cancer</arm_group_label>
    <arm_group_label>Patients with oesophagus cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Preliminary steps : Safety Runs
Safety run of the dual combination:
SBRT at C1D15.
Safety run of the triple combination:
SBRT at C1D15.
Efficacy step
Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with
SBRT at C1D15, then
Durvalumab Q4W alone for up to 9 additional doses</description>
    <arm_group_label>Patients with head and neck squamous cell carcinoma</arm_group_label>
    <arm_group_label>Patients lung cancer</arm_group_label>
    <arm_group_label>Patients with oesophagus cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        I1. Male or Female patients ≥18 years of age or older. I2. Histologically or cytologically
        proven metastatic squamous cell carcinoma (from head and neck, oesophagus or lung) with the
        following features:

          -  Primary tumor in place

          -  Previously treated with at least one prior regimen (chemotherapy, signal transduction
             inhibitors or radiotherapy)

          -  To be treated with radiotherapy at primary tumor site or symptomatic metastatic site
             or menacing metastatic site.

          -  The sites of metastases allowed are: soft tissue, peripheral lung, and liver.

          -  Patients with brain and bone metastasis to be treated with radiotherapy are not
             allowed. Patients with asymptomatic brain metastasis can be included.

          -  The total tumor volume to be irradiated must not exceed 400 cc. I3. At least one tumor
             lesion must be accessible to radiation therapy and at least another tumor site can be
             spared from radiation therapy (unirradiated site). I4. At least one unirradiated and
             one irradiated tumor site must be accessible to tumor biopsy.

        I5. Known availability of an archived block I6. The irradiated and unirradiated tumor sites
        must be mesurable as per RECIST 1.1 I7. Patients must have no history of previous radiation
        therapy within the body area to be irradiated.

        I8. Minimal wash-out periods from previous treatments to C1D1 must be

          -  Any investigational agent &gt; 4 weeks

          -  Bevacizumab &gt; 6 weeks

          -  Chemotherapy &gt; 4 weeks

          -  TKI &gt; 4 weeks

          -  RANK ligand agonists &gt; 6 weeks

          -  Immunosuppressive medication &gt; 28 days, with the exceptions of intranasal, topical,
             and inhaled corticosteroids or systemic corticosteroids at physiological doses, which
             are not to exceeding 10 mg/day of prednisone, or an equivalent corticosteroid

          -  Live attenuated vaccination &gt; 30 days I9. WHO 0-1, Performance Status ECOG of 0-1

        I10. Patients must have adequate organ function defined as follows:

          -  Absolute neutrophil count of ≥ 1500/mm3,

          -  Platelet count≥ 100,000/mm3,

          -  Hemoglobin &gt; 9 g/dL,

          -  Bilirubin ≤ 1.5 times the institutional upper limit of normal (ULN). This will not
             apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent
             hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or
             hepatic pathology), who will be allowed only in consultation with their physician.

          -  Serum ALT and AST ≤2.5 ULN (or if liver metastases are present must be ≤ 5x ULN)

          -  Serum creatinine CL&gt;40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault
             1976) or by 24-hour urine collection for determination of creatinine clearance (see
             formula in section 4.1).

        I11. Patients must be free of significant comorbid conditions that would preclude safe
        administration or completion of protocol therapy.

        I12. Female patients must either be of non-reproductive potential (ie, postmenopausal ≥ 12
        months with no menses without an alternative medical cause OR history of hysterectomy, OR
        history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a
        negative serum pregnancy test upon study entry (within 72 hours before study drug start)
        I13. Fertile men with a female partner of childbearing potential must agree to use male
        codom plus spermicide and childbearing potential women must have agreed to use at least one
        highly effective contraceptive method during treatment on this trial and for up to 180 days
        after the last of dose of Durvalumab + Tremelimumab or 90 days after the last dose of
        Durvalumab monotherapy, whichever is the longer period I14. Patient should understand,
        sign, and date the written voluntary informed consent form prior to any protocol-specific
        procedures performed. Patient should be able and willing to comply with study visits and
        procedures as per protocol.

        I15. Patients must be affiliated to a social security system or beneficiary of the same

        Exclusion Criteria:

        E1. Any situation where the irradiation of the target site would imply reirradiation of a
        formerly irradiated tumor site.

        E2. Patients with any concurrent severe and/or uncontrolled disease which could compromise
        participation in the study including:

          -  Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3
             electrocardiograms (ECGs) using Fredericia's Correction

          -  Active or prior documented autoimmune disease within the past 2 years. Of note,
             patient with vitiligo, Grave's disease or psoriasis not requiring systemic treatment
             (within the past 2 years) are not excluded. Patients with type 1 diabetes or
             hypothyroiditism stable under treatment or not requiring systemic treatment are
             eligible.

          -  Active or prior documented inflammatory bowel disease (eg Crohn's disease, ulcerative
             colitis)

          -  History of primary immunodeficiency

          -  Severe chronic or acute infection such as chronic HBV, HCV and HIV1, 2 infection,
             active tuberculosis infection

          -  Interstitial lung disease that is symptomatic or may interfere with the detection or
             management of suspected drug-related pulmonary toxicity or active non-infectious
             pneumonitis

          -  History of allogenic organ transplant

          -  Uncontrolled diabetes,

          -  Prior history of active bleeding diathesis or patients taking an oral vitamin K
             antagonist (except low-dose Coumadin (warfarin sodium))

          -  Symptomatic congestive heart failure,

          -  Uncontrolled hypertension,

          -  Unstable angina pectoris

          -  Cardiac arrhythmia

          -  Active peptic ulcer disease or gastritis,

          -  Any psychiatric illness/social situations that would limit compliance with study
             requirements or compromise the ability of the subject to give written informed consent

          -  Active secondary malignancy unless the malignancy is not expected to interfere with
             the evaluation of safety and is approved by the sponsor. Examples of the latter
             include basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix,
             and isolated elevation of prostate-specific antigen. Patients with a completely
             treated prior malignancy and no evidence of disease for ≥ 2 years are eligible.

          -  Chronic treatment with corticosteroids or another immunosuppressant

        E3. Patients with tumors that invade major vessels, as shown unequivocally by imaging
        studies

        E4. Patients with central lung metastasis (i.e within 2 cm from hilum) that are cavitary as
        shown unequivocally by imaging studies

        E5. Patients with a history of gross hemoptysis (bright red blood of 1/2 teaspoon or more
        per episode of coughing) ≤ 3 months prior enrolment

        E6. Major surgery within the last 4 weeks prior to entering the study

        E7. Persisting significant toxicities related to prior treatments i.e. ≥ Grade 2 AE
        according to CTCAE V4.03 except alopecia and biological values defined in inclusion
        criteria I10.

        E8. Current or planned use of forbidden concomitant medications :

          -  Any investigational anticancer therapy not specified in this protocol

          -  Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer
             treatment. Concurrent use of hormones for noncancer-related conditions (e.g., insulin
             for diabetes and hormone replacement therapy) is acceptable.

          -  Immunosuppressive medications including, but not limited to systemic corticosteroids
             at doses exceeding 10 mg/day of prednisone or equivalent, methotrexate, azathioprine,
             and TNF-α blockers. Use of immunosuppressive medications for the management of
             investigational product-related AEs or in subjects with contrast allergies is
             acceptable. In addition, use of topical, inhaled and intranasal corticosteroids is
             permitted.

          -  Live attenuated vaccines within 90 days of Durvalumab dosing or within 180 days of
             Durvalumab and Tremelimumab dosing. Inactivated vaccines, such as the injectable
             influenza vaccine, are authorized.

        E9. Any prior Grade ≥ 3 irAE while receiving previous immunotherapy agent or any unresolved
        irAE &gt; Grade 1.

        E10. Prior exposure to any anti-PD-1 or anti-PD-L1 or anti-CTLA4 antibody E11. Known
        allergy or hypersensitivity to humanized antibodies E12. Pregnant or breastfeeding women
        E13. Persons deprived of their freedom or under guardianship, or for whom it would be
        impossible to undergo the medical follow-up required by the trial, for geographic, social
        or psychological reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric DEUTSCH, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric DEUTSCH, MD, PhD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>eric.deutsch@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie LANOY, PhD</last_name>
    <phone>0142114121</phone>
    <phone_ext>+33</phone_ext>
    <email>emilie.lanoy@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric DEUTSCH, MD,PhD</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>eric.deutsch@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emilie LANOY, PhD</last_name>
      <phone>0142114121</phone>
      <phone_ext>+33</phone_ext>
      <email>emilie.lanoy@gustaveroussy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Eric DEUTSCH, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

